Founder — Private Brief

Craig Ebrahimi is the Founder and Director of DarkCell Syndicate, a privately held molecular discovery platform operating outside traditional academic and government systems to generate proprietary, IP-controlled biological assets.

This work began quietly in 2018 with the assembly of DarkCell’s first material set (DCS-1) and the creation of internal datasets developed without external dependency. Select findings were disclosed strategically through recognized scientific forums, including LPSC 52 (2021), establishing signal credibility while retaining full custody of materials, methods, and downstream value. Public visibility was intentional and limited; control was never compromised.

DarkCell was not designed to publish, seek consensus, or optimize for institutional approval. It was designed to own discovery.

Material custody, data exclusivity, and first-use molecular IP are treated as primary assets. Execution is governed by leverage, not exposure.

As of 2026, DCS-1 is deliberately held in reserve. DCM-2 now drives the first wave of active asset creation — peptide and enzyme innovations targeting neuro-regeneration, cellular resilience, and longevity. Each program is structured with clear kill-criteria, synthesis feasibility, and composition-of-matter protection from inception.

Craig is based in Victoria, British Columbia, and operates with a long-horizon mandate. This is not a sprint, and it is not a portfolio of experiments. It is the construction of a molecular advantage that compounds quietly and scales decisively.

DarkCell Syndicate exists to control rare biological signal, convert it into irreversible IP, and deploy it at moments of maximum leverage. Visibility follows ownership. Not the other way around.